Publications While At Healthpartners
A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease
Drugs and Aging.
Double-blind placebo-controlled pilot investigation of the safety of a single dose of rapid-acting intranasal insulin in Down syndrome
Drugs in R&D.
A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein e4 carriers with mild-moderate Alzheimer's disease
Routine cognitive screening in a neurology practice: impact on physician behavior [poster]
Failure on cognitive screening predicts increased healthcare utilization [poster]
Routine cognitive screening in a general neurology clinic: impact on physician behavior [poster]
The effect of intranasal rapid acting insulin on ApoE4 carriers with mild-moderate Alzheimer's disease [poster]
The 6th Vital Sign Project: does cognitive screening in the elderly population improve clinical care [poster]?
Map of science